|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
1986
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L03AB04
|
|
gptkbp:CASNumber
|
76543-88-9
|
|
gptkbp:contraindication
|
autoimmune hepatitis
decompensated liver disease
severe psychiatric disorders
|
|
gptkbp:drugClass
|
interferons
|
|
gptkbp:eliminationHalfLife
|
3-8 hours
|
|
gptkbp:hasMolecularFormula
|
C860H1353N229O255S9
|
|
gptkbp:hasPatent
|
gptkb:US4686187A
|
|
gptkbp:hasProteinSequence
|
true
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB00021
|
|
gptkbp:indication
|
gptkb:hairy_cell_leukemia
gptkb:AIDS-related_Kaposi's_sarcoma
gptkb:chronic_hepatitis_C
chronic hepatitis B
malignant melanoma
|
|
gptkbp:isApprovedDrug
|
true
|
|
gptkbp:isBiotechDrug
|
true
|
|
gptkbp:isRecombinant
|
true
|
|
gptkbp:manufacturer
|
gptkb:Roche
|
|
gptkbp:mechanismOfAction
|
binds to cell surface receptors and induces antiviral, antiproliferative, and immunomodulatory effects
|
|
gptkbp:metabolism
|
renal
|
|
gptkbp:molecularWeight
|
19256.9
|
|
gptkbp:name
|
gptkb:Interferon_alfa-2a
|
|
gptkbp:PubChem_CID
|
gptkb:DB00021
|
|
gptkbp:routeOfAdministration
|
intramuscular
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
gptkb:depression
nausea
anorexia
fatigue
alopecia
myalgia
flu-like symptoms
|
|
gptkbp:status
|
approved
|
|
gptkbp:synonym
|
gptkb:Roferon-A
gptkb:IFN-alpha-2A
gptkb:Interferon_alpha-2A
|
|
gptkbp:target
|
gptkb:interferon_alpha/beta_receptor
|
|
gptkbp:UNII
|
gptkb:P18312
|
|
gptkbp:bfsParent
|
gptkb:secretin
|
|
gptkbp:bfsLayer
|
6
|